实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (2): 177-186.doi: 10.3969/j.issn.1672-5069.2018.02.007
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会
收稿日期:2018-01-02
出版日期:2018-03-10
发布日期:2018-03-19
通讯作者:
范建高,200092 上海交通大学医学院附属新华医院消化内科,E-mail:fattyliver2004@126.com; 魏来,100044 北京大学人民医院,北京大学肝病研究所,E-mail: weilai@pkuph.edu.cn; 庄辉,100191 北京大学医学部,E-mail:zhuangbmu@126.com;
National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association
Received:2018-01-02
Online:2018-03-10
Published:2018-03-19
Contact:
Fan Jiangao,Email:中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018年更新版）[J]. 实用肝脏病杂志, 2018, 21(2): 177-186.
National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:a 2018 update[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 177-186.
| [1] Rinella ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA,2015,313(22):2263-2273. DOI:10.1001/jama.2015.5370 [2] Diehl AM,Day C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med,2017,377(21):2063-2073. DOI:10.1056/NEJMra1503519. [3] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108. DOI:10.1002/hep.27406. [4] Fan JG,Kim SU,Wong VW.New trends on obesity and NAFLD in Asia[J]. J Hepatol,2017,67(4):862-873. DOI:10.1016/j.jhep.2017.06.003. [5] Wang MM,Wang GS,Shen F,et al.Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors[J]. Dig Dis Sci,2014,59(10):2571-2579. DOI:10.1007/s10620-014-3180-9. [6] Fan JG,Jia JD,Li YM,et al.Guidelines for the diagnosis and management of nonalcoholic fatty liver disease:update 2010:(published in Chinese on Chinese Journal of Hepatology 2010;18:163-166)[J]. J Dig Dis,2011,12(1):38-44. DOI: 10.1111/j.1751-2980.2010.00476.x. [7] Review Team,LaBrecque DR,Abbas Z,et al.World Gastroenterology Organisation global guideline:Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. J Clin Gastroenterol,2014,48(6):467-473. DOI:10.1097/MCG.0000000000000116. [8] Wong VW,Chan WK,Chitturi S,et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease Guidelines 2017-Part 1:Definition,risk factors and assessment[J]. J Gastroenterol Hepatol,2018,33(1):70-85. DOI:10.1111/jgh.13857. [9] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357. DOI:10.1002/hep.29367. [10] European Association for the Study of the Liver,European Association for the Study of Diabetes,European Association for the Study of Obesity.Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol,2016,64(6):1388-1402. [11] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84. DOI:10.1002/hep.28431. [12] Zhu JZ,Zhou QY,Wang YM,et al.Prevalence of fatty liver disease and the economy in China:A systematic review[J]. World J Gastroenterol,2015,21(18):5695-5706.DOI:10.3748/wjg.v21.i18.5695. [13] Wong VW,Wong GL,Yeung DK,et al.Incidence of non-alcoholic fatty liver disease in Hong Kong:a population study with paired proton-magnetic resonance spectroscopy[J]. J Hepatol,2015,62(1):182-189. DOI:10.1016/j.jhep.2014.08.041. [14] Xu C,Yu C,Ma H,et al.Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population:the Zhejiang Zhenhai Study[J]. Am J Gastroenterol,2013,108(8):1299-1304. DOI:10.1038/ajg.2013.104.[15] Kwok R,Choi KC,Wong GL,et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:a prospective cohort study[J].Gut,2016,65(8):1359-1368. DOI10.1136/gutjnl-2015-309265. [16] Zhang RN,Zheng RD,Mi YQ,et al.APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3 rs738409 in Chinese Han patients with nonalcoholic fatty liver diseases[J].Dig Dis Sci,2016,61(8):2284-2293. DOI:10.1007/s10620-016-4120-7. [17] Xu L,Ma H,Miao M,et al.Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease:a prospective case-control study[J].J Hepatol,2012,57(5):1153- 1154. DOI:10.1016/j.jhep.2012.05.025. [18] Xu C,Yu C,Xu L,et al.High serum uric acid increases the risk for nonalcoholic Fatty liver disease:a prospective observational study[J]. PLoS One,2010,5(7):e11578. DOI:10.1371/journal.pone.0011578. [19] Ma H,Xu C,Xu L,et al.Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population[J].BMC Gastroenterol,2013,13:3. DOI: 10.1186/1471-230X- 13-3. [20] Xu C,Wan X,Xu L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:One stone hits two birds[J]. J Hepatol,2015,62(6):1412-1419. DOI:10.1016/j.jhep.2015.01.019. [21] Dulai PS,Singh S,Patel J,et al.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease:Systematic review and meta-analysis[J].Hepatology,2017,65(5):1557-1565. DOI:10.1002/hep.29085. [22] Leung JC,Loong TC,Wei JL,et al.Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients[J].Hepatology,2017,65(1):54-64.DOI: 10.1002/hep.28697. [23] Wang Y,Wang B,Shen F,et al.Body mass index and risk of primary liver cancer:a meta-analysis of prospective studies[J].Oncologist,2012,17(11):1461-1468.DOI: 10.1634/theoncologist.2012-0066. [24] Wong VW,Wong GL,Yeung JC,et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram:A prospective cohort study[J].Hepatology,2016,63(3):754-763. DOI:10.1002/hep.28253. [25] Ballestri S,Zona S,Targher G,et al.Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis[J].J Gastroenterol Hepatol,2016,31(5):936-944. DOI: 10.1111/jgh.13264. [26] Chen GY,Cao HX,Li F,et al.New-risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China:Shanghai Baosteel Cohort[J].J Diabetes Investig,2016,7(2):206-211. DOI:10.1111/jdi.12395. [27] Wu S,Wu F,Ding Y,et al.Association of non-alcoholic fatty liver disease with major adverse cardiovascular events:A systematic review and meta-analysis[J]. Sci Rep,2016,6:33386. DOI:10.1038/srep33386. [28] Targher G,Byrne CD,Lonardo A,et al.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J]. J Hepatol,2016,65(3):589-600.DOI:10.1016/j.jhep.2016.05.013. [29] Wu R,Hou F,Wang X,et al.Nonalcoholic fatty liver disease and coronary artery calcification in a northern Chinese population:a cross sectional study[J]. Sci Rep,2017,7(1):9933. DOI:10.1038/s41598-017-09851-5. [30] Musso G,Gambino R,Tabibian JH,et al.Association of non-alcoholic fatty liver disease with chronic kidney disease:a systematic review and meta-analysis[J]. PLoS Med,2014,11(7):e1001680. DOI: 10.1371/journal.pmed.1001680. [31] Zeng J,Sun C,Sun WL,et al.Association between non-invasively diagnosed hepatic steatosis and chronic kidney disease in Chinese adults at a health check-up[J].J Dig Dis,2017,18(4):229-236. DOI:10.1111/1751-2980.12465. [32] Ding W,Fan J,Qin J.Association between nonalcoholic fatty liver disease and colorectal adenoma:a systematic review and meta-analysis[J]. Int J Clin Exp Med,2015,8(1):322-333. [33] Chitturi S,Wong VW,Chan WK,et al.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2:Management and special groups[J]. J Gastroenterol Hepatol,2018,33(1):86-98. DOI:10.1111/jgh.13856. [34] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol,2015,63(1):237-264. DOI:10.1016/j.jhep.2015.04.006. [35] Xu L,Lu W,Li P,et al.A comparison of hepatic steatosis index,controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B[J].Dig Liver Dis,2017,49(8):910-917. DOI:10.1016/j.dld.2017.03.013. [36] Shen F,Zheng RD,Mi YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol,2014,20(16):4702-4711. DOI: 10.3748/wjg.v20.i16.4702. [37] Shen F,Zheng RD,Shi JP,et al.Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J]. Liver Int,2015,35(11):2392-2400. DOI:10.1111/liv.12809. [38] Karlas T,Petroff D,Sasso M,et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol,2017,66(5):1022- 1030. DOI:10.1016/j.jhep.2016.12.022. [39] 沈峰,郑瑞丹,宓余强,等. 细胞角蛋白-18联合受控衰减参数二步法无创鉴别非酒精性脂肪性肝炎的临床研究[J]. 中华肝脏病杂志,2016,24(6):429-434. DOI:10.3760/cma.j.issn.1007-3418.2016.06.007. [40] Bedossa P,FLIP Pathology Consortium.Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis,activity,and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease[J]. Hepatology,2014,60(2):565-575.DOI:10.1002/hep.27173. [41] Xun YH,Fan JG,Zang GQ,et al.Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease[J].J Dig Dis,2012,13(11):588-595. DOI: 10.1111/j.1751-2980.2012.00631.x. [42] Petta S,Wong VW,Cammà C,et al.Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values[J]. Hepatology,2017,65(4):1145-1155. DOI:10.1002/hep.28843. [43] 曾静,孙婉璐,陈光榆,等.FibroTouch与FibroScan肝脏硬度和脂肪定量检测效能的比较[J].中华肝脏病杂志,2016,24(9):652-658. DOI:10.3760/cma.j.issn.1007-3418.2016.09.004. [44] Singh S,Muir AJ,Dieterich DT,et al.American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases[J]. Gastroenterology,2017,152(6):1544-1577. DOI: 10.1053/j.gastro.2017.03.016. [45] Yu C,Xu C,Xu L,et al.Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease[J]. J Hepatol,2012,56(1):241-247. DOI:10.1016/j.jhep.2011.05.027. [46] Nascimbeni F,Pais R,Bellentani S,et al.From NAFLD in clinical practice to answers from guidelines[J]. J Hepatol,2013,59(4):859-871.DOI:10.1016/j.jhep.2013.05.044. [47] Romero-Gómez M,Zelber-Sagi S,Trenell M.Treatment of NAFLD with diet,physical activity and exercise[J]. J Hepatol,2017,67(4):829-846. DOI:10.1016/j.jhep.2017.05.016. [48] Wong VW,Chan RS,Wong GL,et al.Community-based lifestyle modification programme for non-alcoholic fatty liver disease:a randomized controlled trial[J]. J Hepatol,2013,59(3):536-542. DOI:10.1016/j.jhep.2013.04.013. [49] Fan JG,Cao HX.Role of diet and nutritional management in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2013,28 Suppl 4:81-87. DOI: 10.1111/jgh.12244. [50] Zhang HJ,He J,Pan LL,et al.Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease:A Randomized Clinical Trial[J]. JAMA Intern Med,2016,176(8):1074-1082. DOI:10.1001/jamainternmed.2016.3202. [51] Zhang HJ,Pan LL,Ma ZM,et al.Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults:A 1-year follow-up study[J]. Diabetes Obes Metab,2017,19(2):284-289. DOI:10.1111/dom.12809. [52] Argo CK,Patrie JT,Lackner C,et al.Effects of n-3 fish oil on metabolic and histological parameters in NASH:a double-blind,randomized,placebo-controlled tria[J]. J Hepatol,2015,62(1):190-197. DOI:10.1016/j.jhep.2014.08.036. [53] Athyros VG,Tziomalos K,Gossios TD,et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study:a post-hoc analysis[J]. Lancet,2010,376(9756):1916-1922. DOI:10.1016/S0140-6736(10)61272-X. [54] Bril F,Portillo Sanchez P,Lomonaco R,et al.Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis:post hoc analysis of a randomized trial[J]. J Clin Endocrinol Metab,2017,102(8):2950-2961. DOI: 10.1210/jc.2017-00867. [55] Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690. DOI10.1016/S0140- 6736(15)00803-X. [56] Cusi K,Orsak B,Bril F,et al.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus:a randomized trial[J]. Ann Intern Med,2016,165(5):305-315. DOI:10.7326/M15-1774. [57] Brito JP,Montori VM,Davis AM.Metabolic surgery in the treatment algorithm for type 2 diabetes:a joint statement by international diabetes organizations[J]. JAMA,2017,317(6):635-636. DOI:10.1001/jama.2016.20563. [58] Klebanoff MJ,Corey KE,Chhatwal J,et al.Bariatric surgery for nonalcoholic steatohepatitis:A clinical and cost-effectiveness analysis[J]. Hepatology,2017,65(4):1156-1164. DOI:10.1002/hep.28958. [59] 中华医学会感染病学分会,肝脏炎症及其防治专家共识委员会.肝脏炎症及其防治专家共识[J]. 中华肝脏病杂志,2014,22(2):94-103. DOI:10.3760/cma.j.issn. 1007-3418.2014.02.006. [60] Sanyal AJ,Chalasani N,Kowdley KV,et al.Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med,2010,362(18):1675-1685. [61] Neuschwander-Tetri BA,Loomba R,Sanyal AJ,et al.Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):a multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.DOI:10.1016/S0140-6736(14)61933-4. [62] Han Y,Shi JP,Ma AL,et al.Randomized,vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose[J]. Clin Drug Investig,2014,34(1):1-7.DOI: 10.1007/s40261-013-0136-3. [63] Wah Kheong C,Nik Mustapha NR,Mahadeva S.A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol,2017,15(12):1940-1949. DOI: 10.1016/j.cgh.2017.04.016. [64] Newsome PN,Allison ME,Andrews PA,et al.Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis[J].Gut,2012,61(4):484-500. DOI:10.1136/gutjnl-2011-300886. [65] Pais R,Barritt AS 4th,Calmus Y,et al. NAFLD and liver transplantation:Current burden and expected challenges[J]. J Hepatol,2016,65(6):1245-1257. DOI:10.1016/j.jhep.2016.07.033. [66] Ajmera VH,Terrault NA,Harrison SA.Is moderate alcohol use in nonalcoholic fatty liver disease good or bad A critical review[J]. Hepatology,2017,65(6):2090-2099. DOI:10.1002/hep.29055. |
| [1] | 鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769. |
| [2] | 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792. |
| [3] | . 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803. |
| [4] | 石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823. |
| [5] | 吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835. |
| [6] | 邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855. |
| [7] | 段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867. |
| [8] | 陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883. |
| [9] | 马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895. |
| [10] | 曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899. |
| [11] | 曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903. |
| [12] | 冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915. |
| [13] | 黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919. |
| [14] | 李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929. |
| [15] | 张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
